Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center

SIMPLE SUMMARY: BBI608 is an investigational reactive oxygen species generator that affects several molecular and oncogenic pathways, including the STAT3 pathway, and may overcome resistance to immune checkpoint inhibitors. We investigated BBI608 combined with immunotherapy (ipilimumab, pembrolizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Vo, Henry Hiep, Cartwright, Carrie, Song, I-Wen, Karp, Daniel D., Nogueras Gonzalez, Graciela M., Xie, Yuran, Karol, Michael, Hitron, Matthew, Vining, David, Tsimberidou, Apostolia-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909492/
https://www.ncbi.nlm.nih.gov/pubmed/35267638
http://dx.doi.org/10.3390/cancers14051330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909492/
https://www.ncbi.nlm.nih.gov/pubmed/35267638
http://dx.doi.org/10.3390/cancers14051330

Ejemplares similares